Bert Malengier‐Devlies
Impact in
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunology top 10%
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immune cells in cancer
Papers in
- Immunology 12
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 5
- Immune Cell Function and Interaction 3
- IL-33, ST2, and ILC Pathways 3
-
- Autoimmune and Inflammatory Disorders Research 7
- Co-authors
- Patrick Matthys (16 shared papers)Paul Proost (7 shared papers)Carine Helena Wouters (11 shared papers)Mieke Metzemaekers (6 shared papers)Ghislain Opdenakker (4 shared papers)Tania Mitera (9 shared papers)Lien De Somer (5 shared papers)Jennifer Vandooren (3 shared papers)
- Journals
- Frontiers in Immunology (5 papers)European Journal of Immunology (2 papers)Arthritis & Rheumatology (2 papers)The Journal of Immunology (2 papers)JCI Insight (1 paper)
- Partner nations
- BelgiumUnited KingdomNetherlands
In The Last Decade
Bert Malengier‐Devlies
27 papers receiving 873 citations
Peers
Comparison fields: 5 of 74
- Infectious Diseases 343
- Immunology 191
- Hematology 80
- Rehabilitation 21
- Oncology 47
Countries citing papers authored by Bert Malengier‐Devlies
This map shows the geographic impact of Bert Malengier‐Devlies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert Malengier‐Devlies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert Malengier‐Devlies more than expected).
Fields of papers citing papers by Bert Malengier‐Devlies
This network shows the impact of papers produced by Bert Malengier‐Devlies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert Malengier‐Devlies. The network helps show where Bert Malengier‐Devlies may publish in the future.
Co-authors
The 25 scholars most cited alongside Bert Malengier‐Devlies, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 257 | |
| 2 | 2020 | 142 | |
| 3 | 2021 | 48 | |
| 4 | 2021 | 42 | |
| 5 | 2021 | 38 | |
| 6 | 2019 | 37 | |
| 7 | 2021 | 37 | |
| 8 | 2020 | 34 | |
| 9 | 2023 | 34 | |
| 10 | 2022 | 32 | |
| 11 | 2018 | 26 | |
| 12 | 2020 | 26 | |
| 13 | 2023 | 20 | |
| 14 | 2019 | 19 | |
| 15 | 2023 | 19 | |
| 16 | 2022 | 13 | |
| 17 | 2021 | 12 | |
| 18 | 2021 | 9 | |
| 19 | 2021 | 8 | |
| 20 | 2023 | 8 |
About Bert Malengier‐Devlies
Bert Malengier‐Devlies is a scholar working on Immunology, Hematology, Infectious Diseases, Radiology, Nuclear Medicine and Imaging and Rehabilitation, having authored 28 papers that have together received 886 indexed citations. Recurring topics across this work include Autoimmune and Inflammatory Disorders Research (7 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers), COVID-19 Clinical Research Studies (4 papers), Immune Cell Function and Interaction (3 papers), IL-33, ST2, and ILC Pathways (3 papers), Inflammasome and immune disorders (2 papers), Blood disorders and treatments (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Infectious Diseases (343 citations), Immunology (191 citations), Hematology (80 citations), Rehabilitation (21 citations) and Oncology (47 citations). Bert Malengier‐Devlies has collaborated with scholars based in Belgium, United Kingdom and Netherlands. Frequent co-authors include Patrick Matthys, Paul Proost, Carine Helena Wouters, Mieke Metzemaekers, Ghislain Opdenakker, Tania Mitera, Lien De Somer, Jennifer Vandooren, Mieke Gouwy and Jessica Vandenhaute. Their work appears in journals such as Frontiers in Immunology, European Journal of Immunology, Arthritis & Rheumatology, The Journal of Immunology and JCI Insight.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.